Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. The company is conducting Phase Ib clinical trial of Coversin. The company focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.
Website: akaritx.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 25% of quarters (showing a gain of -$0.10 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -5.2% (LTM)

Entry Point: Share price is 3.0% higher than minimum and 96.7% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: AKTX
Share price, USD:  (+0.3%)1.865
year average price 3.3142  


year start price 3.0000 2023-03-30

max close price 5.3480 2023-08-01

min close price 1.8100 2024-03-22

current price 1.8650 2024-03-28
Common stocks: 62 434 624

Dividend Yield:  0.0%
Last revenue growth (y/y):  0.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 116
Net Debt ($m): -7
EV (Enterprise Value): 109
Price to Book: 41.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-12-14GlobeNewsWire

Akari Therapeutics to Present at Biotech Showcase 2024

2023-09-27GlobeNewsWire

Akari Therapeutics to Present at Emerging Growth Conference

2023-07-28PennyStocks

Best Penny Stocks To Buy? 6 To Watch Before Next Week

2023-07-27PennyStocks

Penny Stocks To Buy? 3 To Watch While The Stock Market Is Down
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q3 2023 q2 2022 q2 2022 q1
date 2023-09-30 2023-06-30 2022-06-30 2022-03-31
symbol AKTX AKTX AKTX AKTX
reportedCurrency USD USD USD USD
cik 2M 2M 2M 2M
fillingDate 2023-09-30 2023-09-29 2022-09-27 2022-05-17
acceptedDate 2023-09-28 20:00:00 2023-09-29 08:01:40 2022-09-27 16:30:48 2022-05-17 16:30:36
calendarYear 2023.000 2023.000 2022.000 2022.000
period Q3 Q2 Q2 Q1
revenue 0 0 0 0
costOfRevenue 0 0 0 0
grossProfit 0 0 0 0
grossProfitRatio 0 0 0 0
researchAndDevelopmentExpenses 0 1627.611 3M 2M
generalAndAdministrativeExpenses 0 2977.190 3M 3M
sellingAndMarketingExpenses 0 0 0 0
sellingGeneralAndAdministrativeExpenses 0 2977.190 3M 3M
otherExpenses 0 0 -9205.000 -7109.000
operatingExpenses 0 1528.850 6M 5M
costAndExpenses 0 1528.850 6M 5M
interestIncome 0 29.546 3955.000 4362.000
interestExpense 0 0 3955.000 -67 590
depreciationAndAmortization 0 0.925 -140 482 -69 331
ebitda 0 -4603.875 -6M -5M
ebitdaratio 0 0 0 0
operatingIncome 0 -4604.800 -6M -5M
operatingIncomeRatio 0 0 0 0
totalOtherIncomeExpensesNet 0 3105.496 136 174 67 590
incomeBeforeTax 0 -1499.304 -6M -5M
incomeBeforeTaxRatio 0 0 0 0
incomeTaxExpense 0 -0.000 -136 174 -67 590
netIncome 0 -1499.304 -6M -5M
netIncomeRatio 0 0 0 0
eps 0 -0.340 -0.093 -0.095
epsdiluted 0 -0.340 -0.093 -0.095
weightedAverageShsOut 0 4393.000 59M 54M
weightedAverageShsOutDil 0 4393.669 59M 54M
link Link Link Link
finalLink Link Link Link

Balance Sheet Statement

Property 2023 q3 2023 q2 2023 q1 2022 q3 2022 q2 2022 q1
date 2023-09-30 2023-06-30 2023-03-31 2022-11-08 2022-06-30 2022-03-31
symbol AKTX AKTX AKTX AKTX AKTX AKTX
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2023-09-30 2023-09-29 2023-03-31 2022-11-08 2022-06-30 2022-03-31
acceptedDate 2023-09-28 20:00:00 2023-09-29 08:01:40 2023-03-31 10:31:58 2022-11-08 16:34:28 2022-06-29 20:00:00 2022-03-30 20:00:00
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q3 Q2 Q1 Q3 Q2 Q1
cashAndCashEquivalents 0 7M 0 0 8M 17M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 0 7M 0 0 8M 17M
netReceivables 0 0 0 0 0 0
inventory 0 0 0 0 0 0
otherCurrentAssets 0 186 566 0 0 3M 3M
totalCurrentAssets 0 8M 0 0 11M 19M
propertyPlantEquipmentNet 0 0 0 0 0 0
goodwill 0 0 0 0 0 0
intangibleAssets 0 15 779 0 0 18 844 21 335
goodwillAndIntangibleAssets 0 15 779 0 0 18 844 21 335
longTermInvestments 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 0 0 0 0 0 0
totalNonCurrentAssets 0 15 779 0 0 18 844 21 335
otherAssets 0 0 0 0 0 0
totalAssets 0 8M 0 0 11M 19M
accountPayables 0 1M 0 0 2M 3M
shortTermDebt 0 0 0 0 0 0
taxPayables 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0
otherCurrentLiabilities 0 4M 0 0 1M 2M
totalCurrentLiabilities 0 5M 0 0 3M 6M
longTermDebt 0 0 0 0 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 -2M -3M
totalNonCurrentLiabilities 0 0 0 0 2M 3M
otherLiabilities 0 0 0 0 -2M -3M
capitalLeaseObligations 0 0 0 0 0 0
totalLiabilities 0 5M 0 0 3M 6M
preferredStock 0 0 0 0 0 0
commonStock 0 1M 0 0 593 492 593 492
retainedEarnings 0 -220M 0 0 -211M -205M
accumulatedOtherComprehensiveIncomeLoss 0 -825 877 0 0 -621 557 -573 317
othertotalStockholdersEquity 0 223M 0 0 219M 219M
totalStockholdersEquity 0 3M 0 0 8M 14M
totalEquity 0 3M 0 0 8M 14M
totalLiabilitiesAndStockholdersEquity 0 8M 0 0 11M 19M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 0 8M 0 0 11M 19M
totalInvestments 0 0 0 0 0 0
totalDebt 0 0 0 0 0 0
netDebt 0 -7M 0 0 -8M -17M
link Link Link Link
finalLink Link Link Link

Cash Flow Statement

Property 2023 q3 2023 q2 2022 q2 2022 q1
date 2023-09-30 2023-06-30 2022-06-30 2022-03-31
symbol AKTX AKTX AKTX AKTX
reportedCurrency USD USD USD USD
cik 2M 2M 2M 2M
fillingDate 2023-09-30 2023-09-29 2022-09-27 2022-05-17
acceptedDate 2023-09-28 20:00:00 2023-09-29 08:01:40 2022-09-27 16:30:48 2022-05-17 16:30:36
calendarYear 2023.000 2023.000 2022.000 2022.000
period Q3 Q2 Q2 Q1
netIncome 0 -1499.304 -6M -5M
depreciationAndAmortization 0 0.925 942.000 1006.000
deferredIncomeTax 0 0 0 0
stockBasedCompensation 0 270.763 122 856 98 836
changeInWorkingCapital 0 0 -3M 109 304
accountsReceivables 0 0 0 0
inventory 0 0 0 0
accountsPayables 0 0 0 0
otherWorkingCapital 0 0 0 0
otherNonCashItems 0 -3559.235 -54 142 -82 362
netCashProvidedByOperatingActivities 0 -4786.851 -9M -5M
investmentsInPropertyPlantAndEquipment 0 0 0 0
acquisitionsNet 0 0 0 0
purchasesOfInvestments 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0
otherInvestingActivites 0 0 0 0
netCashUsedForInvestingActivites 0 0 0 0
debtRepayment 0 0 0 0
commonStockIssued 0 0 0 12M
commonStockRepurchased 0 0 0 0
dividendsPaid 0 0 0 0
otherFinancingActivites 0 1751.416 0 0
netCashUsedProvidedByFinancingActivities 0 1751.416 0 12M
effectOfForexChangesOnCash 0 0.807 2404.000 44 375
netChangeInCash 0 -3034.628 -9M 7M
cashAtEndOfPeriod 0 -3034.628 8M 17M
cashAtBeginningOfPeriod 0 0 17M 9M
operatingCashFlow 0 -4786.851 -9M -5M
capitalExpenditure 0 0 0 0
freeCashFlow 0 -4786.851 -9M -5M
link Link Link Link
finalLink Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2023-12-01 13:00 ET
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors
2023-11-16 13:00 ET
Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
2023-11-06 13:00 ET
Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
2023-09-29 12:00 ET
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
2023-09-29 12:00 ET
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
2023-09-27 12:00 ET
Akari Therapeutics to Present at Emerging Growth Conference
2023-09-27 12:00 ET
Akari Therapeutics to Present at Emerging Growth Conference
2023-09-21 12:00 ET
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit
2023-09-21 12:00 ET
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit
2023-09-19 12:00 ET
Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs
2023-09-19 12:00 ET
Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs
2023-09-05 12:00 ET
Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
2023-09-05 12:00 ET
Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
2023-08-18 12:00 ET
Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials
2023-08-18 12:00 ET
Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials
2023-08-15 12:00 ET
Akari Therapeutics, Plc Announces ADS Ratio Change
2023-08-15 12:00 ET
Akari Therapeutics, Plc Announces ADS Ratio Change
2023-08-02 12:00 ET
Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs
2023-08-02 12:00 ET
Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs
2023-07-27 12:00 ET
Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation
2023-07-27 12:00 ET
Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation
2023-07-19 12:00 ET
Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer
2023-07-19 12:00 ET
Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer
2023-07-13 12:00 ET
Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA
2023-07-13 12:00 ET
Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA
2023-07-11 12:00 ET
Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy
2023-07-11 12:00 ET
Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy
2023-07-06 12:00 ET
Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation
2023-07-06 12:00 ET
Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation
2023-07-05 12:00 ET
Akari Therapeutics Appoints Industry Veteran Wa’el Hashad to Board of Directors
2023-07-05 12:00 ET
Akari Therapeutics Appoints Industry Veteran Wa’el Hashad to Board of Directors
2023-05-16 12:00 ET
Akari Therapeutics to Participate in A.G.P.’s Virtual Healthcare Conference
2023-05-16 12:00 ET
Akari Therapeutics to Participate in A.G.P.’s Virtual Healthcare Conference
2023-05-01 12:00 ET
Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights
2023-05-01 12:00 ET
Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights
2023-04-25 20:15 ET
Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement
2023-04-25 20:15 ET
Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement
2023-04-14 12:00 ET
Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs
2023-04-14 12:00 ET
Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs
2023-04-11 12:00 ET
Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology
2023-04-11 12:00 ET
Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology
2023-04-03 12:00 ET
Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting
2023-04-03 12:00 ET
Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting
2023-03-30 13:09 ET
Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering
2023-03-30 13:09 ET
Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering
2023-03-29 12:00 ET
Poland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study
2023-03-29 12:00 ET
Poland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study
2023-02-21 13:00 ET
Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings
2023-02-21 13:00 ET
Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings
2023-02-15 13:00 ET
Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)
2023-02-15 13:00 ET
Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)
2023-02-13 13:00 ET
Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in Adults
2023-02-13 13:00 ET
Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in Adults
2023-01-04 13:00 ET
Akari Therapeutics to Present at Biotech Showcase™ 2023
2023-01-04 13:00 ET
Akari Therapeutics to Present at Biotech Showcase™ 2023
2022-12-01 13:00 ET
Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference
2022-12-01 13:00 ET
Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference
2022-11-22 13:00 ET
Akari Therapeutics to Participate in the Ophthalmology Day at BTIG
2022-11-22 13:00 ET
Akari Therapeutics to Participate in the Ophthalmology Day at BTIG
2022-11-10 13:00 ET
Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA
2022-11-10 13:00 ET
Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA
2022-11-09 13:00 ET
Akari Therapeutics to Participate in the Jefferies London Healthcare Conference
2022-11-09 13:00 ET
Akari Therapeutics to Participate in the Jefferies London Healthcare Conference
2022-11-08 13:00 ET
Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer
2022-11-08 13:00 ET
Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer
2022-10-31 12:00 ET
Akari Therapeutics to Participate in the Sidoti November 2022 Virtual Micro-Cap Conference
2022-10-31 12:00 ET
Akari Therapeutics to Participate in the Sidoti November 2022 Virtual Micro-Cap Conference
2022-10-28 20:30 ET
Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
2022-10-28 20:30 ET
Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
2022-09-27 12:00 ET
Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress
2022-09-27 12:00 ET
Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress
2022-09-22 12:00 ET
Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference
2022-09-22 12:00 ET
Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference
2022-09-12 12:00 ET
Akari Therapeutics Announces $12.75 Million Registered Direct Offering
2022-09-12 12:00 ET
Akari Therapeutics Announces $12.75 Million Registered Direct Offering
2022-08-01 12:00 ET
Akari Therapeutics Narrows Pipeline Focus
2022-08-01 12:00 ET
Akari Therapeutics Narrows Pipeline Focus
2022-07-28 12:00 ET
Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy
2022-07-28 12:00 ET
Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy
2022-07-20 10:00 ET
Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress
2022-07-20 10:00 ET
Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress
2022-07-07 12:00 ET
Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)
2022-07-07 12:00 ET
Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)
2022-06-13 11:00 ET
Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies
2022-05-19 20:05 ET
Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting
2022-05-16 10:00 ET
Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress
2022-05-11 11:00 ET
Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting
2022-05-10 11:00 ET
Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology
2022-05-09 11:00 ET
Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC)
2022-03-21 12:00 ET
Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the Surface of the Eye at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
2022-03-09 12:30 ET
Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch
2022-03-08 16:45 ET
Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering
2022-03-02 12:00 ET
Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer
2022-02-28 14:12 ET
Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma
2022-02-11 12:00 ET
Akari Therapeutics to Present at BIO CEO & Investor Conference
2022-01-26 13:30 ET
Akari Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases
2022-01-19 13:30 ET
FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies
2022-01-04 12:00 ET
Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
2021-12-30 16:03 ET
Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering
2021-12-03 12:45 ET
Akari Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Clinical Progress
2021-12-01 13:30 ET
Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders
2021-10-26 12:00 ET
Akari Therapeutics Announces Presentation at Annual Complement-Based Drug Development Summit
2021-10-25 12:30 ET
Akari Therapeutics Announces New Data with Nomacopan from its Surface of the Eye Program
2021-09-22 13:00 ET
Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
2021-09-22 12:30 ET
Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress
2021-09-10 12:30 ET
Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium
2021-09-07 11:00 ET
Akari Therapeutics to Present at the H.C. Wainwright Global Investment Conference
2021-07-07 13:15 ET
Akari Therapeutics Announces Private Placement
2021-06-29 20:01 ET
Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Clinical Progress
2021-04-28 12:00 ET
Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid
2021-04-22 11:30 ET
Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase III Trial Design at American Academy of Dermatology Association Virtual Meeting Experience
2021-04-20 22:40 ET
Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress
2021-04-12 14:16 ET
Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)
2021-03-04 13:30 ET
Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) for Nomacopan in Trauma
2021-02-25 14:07 ET
Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis
2021-02-01 14:29 ET
Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease
2021-01-06 14:32 ET
Akari Therapeutics to Participate in Two January Virtual Investor Conferences
2020-12-11 14:00 ET
Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress
2020-12-11 13:55 ET
Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
2020-12-03 15:00 ET
Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease
2020-10-27 13:00 ET
Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress October 29
2020-10-06 12:30 ET
Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia
2020-10-01 13:00 ET
Akari Therapeutics Announces Successful Scientific Advice Meeting with the European Medicines Agency (EMA) Establishing a Clear Path in Both U.S. and Europe for a Pivotal Phase III Study of Nomacopan for Treatment of Bullous Pemphigoid
2020-09-29 13:30 ET
Akari Therapeutics to Present Its Phase III Plans at the International Pemphigus & Pemphigoid Foundation (IPPF) Patient Education Conference
2020-09-10 12:00 ET
Akari Therapeutics to Participate in Two September Virtual Investor Conferences
2020-09-01 12:30 ET
Akari Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Recent Clinical Progress
2020-08-31 11:00 ET
Akari Therapeutics Announces International Clinical Development Program of Nomacopan for the Potential Treatment of COVID-19 Pneumonia
2020-08-12 12:23 ET
Akari Therapeutics Announces Successful End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study for Treatment of Bullous Pemphigoid With Nomacopan
2020-07-01 13:16 ET
Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC
2020-07-01 13:15 ET
Akari Therapeutics Announces Appointment of Chief Financial Officer
2020-05-29 11:00 ET
Akari Therapeutics Reports First Quarter 2020 Financial Results and Highlights Recent Clinical Progress
2020-05-21 15:32 ET
Akari Therapeutics Receives Positive EMA Opinion on Orphan Designation for Nomacopan for Bullous Pemphigoid
2020-05-04 11:30 ET
Akari Therapeutics to Participate in STRH Life Sciences Virtual Meeting Series
2020-05-01 11:00 ET
Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients
2020-03-31 12:00 ET
Akari Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
2020-03-04 13:52 ET
Akari Therapeutics, Plc Announces Closing of $9.5 Million Private Placement
2020-02-20 22:34 ET
Akari Therapeutics, Plc Announces Private Placement
2020-01-27 13:58 ET
Akari Therapeutics Announces Preclinical Ophthalmic Data Showing Nomacopan Reduces Both Vascular Endothelial Growth Factor (VEGF) and Retinal Inflammation Supporting Nomacopan as a Potential Treatment Option for Back-of-the-Eye Diseases
2020-01-10 14:29 ET
Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study
2019-12-23 13:45 ET
Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) Following the Opening of its IND
2019-12-02 13:30 ET
Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting  
2019-11-04 13:33 ET
Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress
2019-10-14 12:37 ET
Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC Trial
2019-10-10 12:45 ET
Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress
2019-09-18 12:00 ET
Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference
2019-09-13 12:00 ET
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid
2019-08-30 13:34 ET
Thinking about buying stock in Aurora Cannabis, Akari Therapeutics, Big Lots, Campbell Soup, or Walt Disney Co?
2019-08-14 13:31 ET
Thinking about buying stock in Aurora Cannabis, Akari Therapeutics, Walt Disney Co, Presidio, or Tilray?

SEC forms

Show financial reports only

SEC form 6
2023-12-01 08:00 ET
Akari Therapeutics published news for 2023 q3
SEC form 6
2023-11-16 08:00 ET
Akari Therapeutics published news for 2023 q3
SEC form 6
2023-09-29 00:00 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-09-21 08:00 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-09-05 09:00 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-08-18 08:00 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-08-15 08:00 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-08-02 08:00 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-07-27 08:00 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-07-25 08:30 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-07-19 08:00 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-07-13 08:30 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-07-11 08:30 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-07-07 16:30 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-07-06 08:30 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-07-05 08:30 ET
Akari Therapeutics published news for 2023 q2
SEC form 6
2023-06-30 16:30 ET
Akari Therapeutics published news for 2023 q1
SEC form 6
2023-06-06 08:59 ET
Akari Therapeutics published news for 2023 q1
SEC form 6
2023-05-22 08:30 ET
Akari Therapeutics published news for 2023 q1
SEC form 6
2023-05-05 08:00 ET
Akari Therapeutics published news for 2023 q1
SEC form 6
2023-05-03 17:00 ET
Akari Therapeutics published news for 2023 q1
SEC form 6
2023-05-01 08:05 ET
Akari Therapeutics published news for 2023 q1
SEC form 6
2023-04-28 18:29 ET
Akari Therapeutics published news for 2023 q1
SEC form 6
2023-04-25 16:20 ET
Akari Therapeutics published news for 2023 q1
SEC form 6
2023-03-31 10:31 ET
Akari Therapeutics published news for 2022 q4
SEC form 6
2023-03-29 09:00 ET
Akari Therapeutics published news for 2022 q4
SEC form 6
2023-03-28 09:03 ET
Akari Therapeutics published news for 2022 q4
SEC form 6
2023-03-13 09:00 ET
Akari Therapeutics published news for 2022 q4
SEC form 6
2023-02-21 08:06 ET
Akari Therapeutics published news for 2022 q4
SEC form 6
2023-02-15 16:30 ET
Akari Therapeutics published news for 2022 q4
SEC form 6
2023-02-15 08:05 ET
Akari Therapeutics published news for 2022 q4
SEC form 6
2023-02-13 08:05 ET
Akari Therapeutics published news for 2022 q4
SEC form 6
2022-11-10 16:44 ET
Akari Therapeutics published news for 2022 q3
SEC form 6
2022-11-08 16:34 ET
Akari Therapeutics published news for 2022 q3
SEC form 6
2022-10-28 16:34 ET
Akari Therapeutics published news for 2022 q3
SEC form 6
2022-09-27 00:00 ET
Akari Therapeutics published news for 2022 q2
SEC form 6
2022-09-14 12:02 ET
Akari Therapeutics published news for 2022 q2
SEC form 6
2022-08-01 17:00 ET
Akari Therapeutics published news for 2022 q2
SEC form 6
2022-07-29 17:00 ET
Akari Therapeutics published news for 2022 q2
SEC form 6
2022-07-20 16:42 ET
Akari Therapeutics published news for 2022 q2
SEC form 6
2022-07-07 19:21 ET
Akari Therapeutics published news for 2022 q2
SEC form 6
2022-07-05 17:21 ET
Akari Therapeutics published news for 2022 q2
SEC form 6
2022-06-15 19:40 ET
Akari Therapeutics published news for 2022 q1
SEC form 6
2022-06-06 18:41 ET
Akari Therapeutics published news for 2022 q1
SEC form 6
2022-05-20 16:30 ET
Akari Therapeutics published news for 2022 q1
SEC form 6
2022-05-17 16:30 ET
Akari Therapeutics published news for 2022 q1
SEC form 6
2022-05-16 06:04 ET
Akari Therapeutics published news for 2022 q1
SEC form 6
2022-05-11 08:52 ET
Akari Therapeutics published news for 2022 q1
SEC form 6
2022-05-09 16:52 ET
Akari Therapeutics published news for 2022 q1
SEC form 6
2022-04-29 16:34 ET
Akari Therapeutics published news for 2022 q1
SEC form 6
2022-03-09 21:35 ET
Akari Therapeutics published news for 2021 q4
SEC form 6
2022-03-04 16:58 ET
Akari Therapeutics published news for 2021 q4
SEC form 6
2022-02-28 17:15 ET
Akari Therapeutics published news for 2021 q4
SEC form 6
2022-01-26 16:30 ET
Akari Therapeutics published news for 2021 q4
SEC form 6
2022-01-19 16:30 ET
Akari Therapeutics published news for 2021 q4
SEC form 6
2022-01-03 21:40 ET
Akari Therapeutics published news for 2021 q4
SEC form 6
2021-12-21 16:30 ET
Akari Therapeutics published news for 2021 q3
SEC form 6
2021-12-03 16:30 ET
Akari Therapeutics published news for 2021 q3
SEC form 6
2021-12-01 17:16 ET
Akari Therapeutics published news for 2021 q3
SEC form 6
2021-10-25 16:48 ET
Akari Therapeutics published news for 2021 q3
SEC form 6
2021-09-22 00:00 ET
Akari Therapeutics published news for 2021 q2
SEC form 6
2021-07-20 17:19 ET
Akari Therapeutics published news for 2021 q2
SEC form 6
2021-07-07 16:15 ET
Akari Therapeutics published news for 2021 q2
SEC form 6
2021-07-01 17:39 ET
Akari Therapeutics published news for 2021 q2
SEC form 6
2021-06-29 16:47 ET
Akari Therapeutics published news for 2021 q1
SEC form 6
2021-06-07 17:30 ET
Akari Therapeutics published news for 2021 q1
SEC form 6
2021-04-28 16:54 ET
Akari Therapeutics published news for 2021 q1
SEC form 6
2021-04-20 18:48 ET
Akari Therapeutics published news for 2021 q1
SEC form 6
2021-04-20 18:33 ET
Akari Therapeutics published news for 2021 q1
SEC form 6
2021-04-12 16:43 ET
Akari Therapeutics published news for 2021 q1
SEC form 6
2021-03-04 17:22 ET
Akari Therapeutics published news for 2020 q4
SEC form 6
2021-02-25 16:31 ET
Akari Therapeutics published news for 2020 q4
SEC form 6
2021-02-01 17:34 ET
Akari Therapeutics published news for 2020 q4
SEC form 6
2020-12-11 16:20 ET
Akari Therapeutics published news for 2020 q3
SEC form 6
2020-12-11 16:19 ET
Akari Therapeutics published news for 2020 q3
SEC form 6
2020-12-09 16:15 ET
Akari Therapeutics published news for 2020 q3
SEC form 6
2020-12-03 16:37 ET
Akari Therapeutics published news for 2020 q3
SEC form 6
2020-11-16 09:40 ET
Akari Therapeutics published news for 2020 q3
SEC form 6
2020-10-06 09:28 ET
Akari Therapeutics published news for 2020 q3
SEC form 6
2020-10-01 09:30 ET
Akari Therapeutics published news for 2020 q3